Rein Therapeutics, Inc. Common Stock (RNTX)
PHARMACEUTICAL PREPARATIONS
Rein Therapeutics, Inc. Common Stock (RNTX) is listed on Nasdaq, where it has traded since June 29, 2017.
- Listed On
- Nasdaq
- Listed Since
- June 29, 2017
- Employees
- 10
- Market Cap
- $69M
About Rein Therapeutics, Inc. Common Stock
Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 57 institutions reported holding RNTX, with 40.8 million shares worth $42.4 million in aggregate. The largest reported holder was Voss Capital, with 5.3 million shares worth $5.5 million. Of the 5 largest holders listed below, 1 opened a new position in RNTX and 4 added shares during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Voss Capital | 5,261,921 | $5M | Added 19.91% |
| Cable Car Capital | 5,195,000 | $5M | Added 1136.9% |
| Adar1 Capital Management | 4,500,000 | $5M | New position |
| Vanguard | 3,773,199 | $4M | Added 223.66% |
| Bios Capital Management | 2,982,375 | $3M | Added 50.44% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is RNTX?
Rein Therapeutics, Inc. Common Stock (RNTX) is listed on Nasdaq, where it has traded since June 29, 2017.
Who are the largest institutional holders of RNTX?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of RNTX were Voss Capital, Cable Car Capital and Adar1 Capital Management.
How many institutions own RNTX?
57 institutions reported a position in RNTX for the quarter ended June 30, 2026, worth $42.4 million in total.
Did institutions buy or sell RNTX last quarter?
Of the 5 largest reported holders, 1 opened a new position in RNTX and 4 added shares during the quarter. Every reported holder and its change is on the SentiSense ownership page for RNTX.
Every reported institutional holder, plus insider and congressional trades in RNTX, on SentiSense.